Concepedia

Gerald Chu

GC

Statistics

Publications

6

Citations

1.4K

H-Index

6

Active since

2007

Affiliations

Janssen (United States)(Current)

Dana-Farber Cancer Institute

Brigham and Women's Hospital

Harvard University

Gerald Chu is an author at Janssen (United States) specializing in oncology, medicine, and cd3-directed bispecific antibodies.

ORCID

Publications per year

2007–2020

6

Publications

6

FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis

Ji-Hye Paik, Ramya Kollipara, Gerald Chu et al. · Cell · 2007 · 1K citations · Full text

, , +14

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Kodandaram Pillarisetti, Suzanne C. Edavettal, Mark Mendonça et al. · Blood · 2020 · 163 citations · Full text

, , +17

FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis

Boyi Gan, Carol S. Lim, Gerald Chu et al. · Cancer Cell · 2010 · 143 citations · Full text

, , +11

A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia

Priyanka Nair-Gupta, Michael Diem, Dara Reeves et al. · Blood Advances · 2020 · 43 citations · Full text

, , +17

Development of a CD123xCD3 Bispecific Antibody (JNJ-63709178) for the Treatment of Acute Myeloid Leukemia (AML)

François Gaudet, Jennifer F. Nemeth, Ronan McDaid et al. · Blood · 2016 · 30 citations

, , +14

1–5 of 6